Provided by Tiger Trade Technology Pte. Ltd.

Biogen

225.88
-1.1900-0.52%
Pre-market: 225.880.00000.00%08:19 EDT
Volume:1.55M
Turnover:352.50M
Market Cap:33.35B
PE:40.12
High:229.36
Open:227.23
Low:225.51
Close:227.07
52wk High:230.49
52wk Low:138.00
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.30
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.77
PE(LYR):25.70

Loading ...

Biogen - Diranersen Shows 50–65% Mean Reduction in Csf Total Tau and Brain Tau Pathology

THOMSON REUTERS
·
Jul 14

Biogen Presents Phase 2 Celia Data at Aaic Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

THOMSON REUTERS
·
Jul 14

Biogen's Alzheimer's Drug Lowers Toxic Protein, but Results were Mixed

Reuters
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
Jul 14

Piper Sandler Remains a Buy on Biogen (BIIB)

TIPRANKS
·
Jul 14

Canaccord Genuity Remains a Buy on Biogen (BIIB)

TIPRANKS
·
Jul 14

IQLIK Approval Seen as Commercial Enhancer, Not Fundamental Shift, as Biogen Neutral Rating and $200 Price Target Remain Unchanged

TIPRANKS
·
Jul 14

Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector?

Simply Wall St.
·
Jul 14

Eisai Inc: Leqembi Iqlik Initiation Dosing Expected to be Available in U.S. Late August 2026

THOMSON REUTERS
·
Jul 14

FDA Approves Leqembi Iqlik® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

THOMSON REUTERS
·
Jul 14

Biogen Inc. Stock Rallies 5.0%, Outperforms Peers

Dow Jones
·
Jul 14

Movement Alert|Biogen Rises 5.26% in Regular Trading, FDA Approves Leqembi Subcutaneous Injection New Initiation Regimen

Market Focus
·
Jul 14

Early subQ approval should help Biogen regain market share, says RBC

TIPRANKS
·
Jul 14

Biogen Rises After FDA Clears At-home Use of Alzheimer's Drug

Reuters
·
Jul 14

Shares of Biogen up 5% After US FDA Approves Subcutaneous Starting Dose for Alzheimer's Drug Leqembi

THOMSON REUTERS
·
Jul 14

FDA: Approves New Starting Dosage Regimen for Leqembi Subcutaneous Formulation for Alzheimer’s Disease Treatment

THOMSON REUTERS
·
Jul 14

Dow Jones Top Company Headlines at 11 am ET: Meta Lifts Cost of Louisiana Data Center to $50 Billion | Intel ...

Dow Jones
·
Jul 13

BMO Capital Sticks to Its Hold Rating for Biogen (BIIB)

TIPRANKS
·
Jul 13

Biogen Stock is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details

Dow Jones
·
Jul 13

Wedbush Raises Price Target on Biogen to $201 From $196, Keeps Neutral Rating

MT Newswires Live
·
Jul 13